Pytell Jarratt D, Robertson Mariah L, Han Benjamin H, Martinez Noelle G
Department of Medicine, University of Colorado School of Medicine, Mail Stop B180, 12631 E. 17 th Ave, Aurora, CO 80045, USA.
Department of General Internal Medicine, Denver Health Medical Center, Denver, CO, USA.
Curr Geriatr Rep. 2025;14(1). doi: 10.1007/s13670-025-00431-4. Epub 2025 May 3.
The review synthesizes current literature on the epidemiology, treatment outcomes, and co-occurring conditions of opioid use disorder (OUD) in older adults, framed through the OUD cascade of care model.
The prevalence of OUD among older adults has risen significantly, with Medicare data showing an increase from 4.6 to 15.7 per 1,000 beneficiaries between 2013 and 2018. Hospitalizations and overdose deaths have also escalated, particularly among racially minoritized groups. Despite policy changes expanding access to medications for OUD, including the removal of the X-Waiver and Medicare's coverage of opioid treatment programs, treatment rates remain low, and disparities are present based on geographic location, race, ethnicity, and gender. Studies indicate that buprenorphine and methadone significantly reduce mortality risk, yet optimal dosing and delivery models for older adults remain underexplored. Additionally, older adults with OUD experience high rates of comorbidities, including cardiovascular disease, psychiatric conditions, and chronic pain, further complicating the initiation and maintenance of medications for OUD.
Older adults with OUD are growing and while treatment is increasing, research and best practices on age-friendly approaches to screening, treatment, and harm reduction remain unknown. The growing burden of OUD in this population underscores the urgent need for research on tailored interventions, particularly regarding medications for OUD initiation, polypharmacy management, and care delivery models that accommodate mobility and cognitive impairments. Expanding harm reduction strategies and integrating OUD treatment into general medical settings can enhance access and improve outcomes for older adults.
本综述综合了关于老年人阿片类物质使用障碍(OUD)的流行病学、治疗结果和共病情况的当前文献,并通过OUD照护级联模型进行阐述。
老年人中OUD的患病率显著上升,医疗保险数据显示,2013年至2018年间,每1000名受益人的患病率从4.6增至15.7。住院率和过量用药死亡率也有所上升,尤其是在少数族裔群体中。尽管政策有所改变,扩大了获得OUD药物的途径,包括取消X豁免以及医疗保险对阿片类物质治疗项目的覆盖,但治疗率仍然很低,并且在地理位置、种族、民族和性别方面存在差异。研究表明,丁丙诺啡和美沙酮可显著降低死亡风险,但针对老年人的最佳剂量和给药模式仍未得到充分探索。此外,患有OUD的老年人共病率很高,包括心血管疾病、精神疾病和慢性疼痛,这进一步使OUD药物的启动和维持变得复杂。
患有OUD的老年人数量在增加,虽然治疗也在增加,但关于适合老年人的筛查、治疗和减少伤害方法的研究和最佳实践仍然未知。该人群中OUD负担的增加凸显了对量身定制干预措施进行研究的迫切需求,特别是关于启动OUD药物、多药治疗管理以及适应行动能力和认知障碍的护理提供模式。扩大减少伤害策略并将OUD治疗纳入普通医疗环境可以增加老年人获得治疗的机会并改善治疗结果。